Clune & Associates’s AbbVie ABBV Stock Holding History

Clune & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.03M	Buy	19,240 +207	+1%	+$53.1K	0.77%	34
2026 Q2	$4.79M	Sell	19,033 -298	-2%	-$64.1K	0.72%	35
2026 Q1	$4.2M	Buy	19,331 +895	+5%	+$199K	0.79%	36
2025 Q4	$4.21M	Buy	18,436 +419	+2%	+$95.4K	0.91%	36
2025 Q3	$4.17M	Sell	18,017 -85	-0.5%	-$17.3K	1.04%	30
2025 Q2	$3.36M	Sell	18,102 -1,151	-6%	-$214K	0.92%	34
2025 Q1	$4.03M	Buy	19,253 +90	+0.5%	+$17.5K	1.24%	23
2024 Q4	$3.41M	Buy	+19,163	New	+$3.52M	1.13%	26

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Clune & Associates's ABBV Position: Q3 2026 in Review

Clune & Associates increased its AbbVie (ABBV) stake by 1.1% in Q3 2026, buying an estimated $53.1K and bringing the position to 19,240 shares worth $5.03M. The position accounts for 0.77% of the portfolio, ranked #34.

Clune & Associates first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. 1,113 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Clune & Associates held 19,240 shares of AbbVie worth $5.03M as of Q3 2026.
Clune & Associates bought 207 AbbVie shares in Q3 2026, an estimated $53.1K.
AbbVie made up 0.77% of Clune & Associates's portfolio in Q3 2026, its #34 holding.
Clune & Associates first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
1,113 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Clune & Associates's 13F filing for Q3 2026, filed 8 Oct 2026.